FrederickMFellinMD

Oncology • Philadelphia, PA

Breast Cancer, Hematologic Oncology

Assistant Professor of Medicine, Thomas Jefferson University

Join to view full profile

Dr. Fellin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fellin's full profile

Already have an account?

Office
925 Chestnut St
Suite 420
Philadelphia, PA 19107
Phone+1 215-955-8874

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1988 - 1989
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1985 - 1988
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1980 - 1983
West Virginia UniversityInternship, Transitional Year, 1979 - 1980
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1979

Certifications & Licensure

DE State Medical License 2017 - 2025
PA State Medical License 1981 - 2024
NJ State Medical License 2017 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer Start of enrollment: 2011 Dec 01
Unknown status
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Start of enrollment: 2013 May 21
Completed
Phase 2
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Start of enrollment: 2013 Apr 25
Completed
Phase 2
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.
Maysa Abu-Khalaf, Chun Wang, Zhenchao Zhang, Rui Luo, Weelic Chong
Cancers. 2022-06-10
27 citations
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Chun Wang, Zhaomei Mu, Zhong Ye, Zhenchao Zhang, Maysa M. Abu-Khalaf
Breast Cancer Research and Treatment. 2020-05-04
31 citations
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
Zhong Ye, Chun Wang, Shaogui Wan, Zhaomei Mu, Zhenchao Zhang
European Journal of Cancer. 2019-01-01

Professional Memberships

American College of Physicians - ACP
Fellow
American Society of Clinical Oncology - ASCO
Member
American Medical Association - AMA
Member
American Society of Hematology - ASH
Member